{"id":"W4412428663","doi":"10.1001/jamanetworkopen.2025.18440","title":"Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Population; Randomized controlled trial; Chemoradiotherapy; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006791363,0.0002593689,0.0005909929,0.00006604491,0.0002617434,0.0001930664,0.0004660793,0.0001474921,0.0009740744],"category_scores_gemma":[0.00001942754,0.0001833581,0.0001018545,0.0006601751,0.00005883532,0.0001586605,0.0002124134,0.0002062385,0.000002529782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002788061,"about_ca_system_score_gemma":0.0009211463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003643553,"about_ca_topic_score_gemma":0.003807357,"domain_scores_codex":[0.9983472,0.00004008653,0.0003923878,0.0004508966,0.0002028539,0.0005666087],"domain_scores_gemma":[0.9988554,0.0001798646,0.0001852528,0.000504775,0.0001621124,0.000112595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2658233,0.001020008,0.06086731,0.001424451,0.002708139,0.00007455146,0.0006422405,0.002023403,0.004644339,0.000209039,0.650984,0.009579211],"study_design_scores_gemma":[0.1748442,0.003419725,0.1103433,0.005620033,0.0012268,0.00001358752,0.0006462812,0.02594966,0.008826316,0.00002827293,0.6681245,0.000957376],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8952047,0.004750383,0.01444188,0.01048064,0.001990954,0.01763444,0.0003644897,0.0001551559,0.05497736],"genre_scores_gemma":[0.5543896,0.0007980289,0.005412743,0.011546,0.000573493,0.00134687,0.0002103898,0.00009606041,0.4256268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3706495,"threshold_uncertainty_score":0.9999391,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02943612872246778,"score_gpt":0.3219153829988494,"score_spread":0.2924792542763816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}